Trial Profile
A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cusatuzumab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Gemcitabine; Paclitaxel
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- Sponsors argenx
- 07 Aug 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2018 Planned End Date changed from 1 Jul 2017 to 1 Jun 2018.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.